Company Filing History:
Years Active: 2024-2025
Title: Yalda Sedaghat: Innovator in Antibody Research
Introduction
Yalda Sedaghat is a prominent inventor based in Hamburg, Germany. She has made significant contributions to the field of antibody research, particularly focusing on human Semaphorin 3A (Sema3A). With a total of 2 patents to her name, her work has the potential to impact various therapeutic applications.
Latest Patents
Yalda's latest patents include innovative developments in anti-Sema3A antibodies. The first patent describes an isolated antibody or antigen-binding fragment that specifically binds to human Sema3A. This patent also covers an antibody conjugate and a pharmaceutical composition that incorporates the isolated antibody. The second patent further elaborates on the characteristics of the isolated antibody, detailing its binding affinity and cross-reactivity with Sema3A from various species, including mouse and rat. It also highlights the antibody's ability to inhibit the activity of human Sema3A in multiple in vitro assays.
Career Highlights
Yalda Sedaghat is currently employed at Bayer Aktiengesellschaft, where she continues her research and development in the field of biotechnology. Her work at Bayer has allowed her to collaborate with leading experts in the industry, enhancing her contributions to scientific advancements.
Collaborations
Some of Yalda's notable coworkers include Dorian Schönfeld and Karoline Dröbner, who have also played significant roles in their respective fields. Their collaborative efforts contribute to the innovative environment at Bayer.
Conclusion
Yalda Sedaghat is a remarkable inventor whose work in antibody research is paving the way for new therapeutic options. Her patents reflect her dedication to advancing medical science and improving patient outcomes.